Eligo Bioscience Revenue and Competitors

Paris, France

Location

N/A

Total Funding

Fintech

Industry

Estimated Revenue & Valuation

  • Eligo Bioscience's estimated annual revenue is currently $6.3M per year.(i)
  • Eligo Bioscience's estimated revenue per employee is $117,000

Employee Data

  • Eligo Bioscience has 54 Employees.(i)
  • Eligo Bioscience grew their employee count by -4% last year.

Eligo Bioscience's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$184.9M1016-3%N/AN/A
#2
$132M7252%N/AN/A
#3
$27.5M1926%N/AN/A
#4
$92.1M567-3%N/AN/A
#5
$26M182-14%N/AN/A
#6
$49.2M3035%N/AN/A
#7
$108.3M65619%$311.8MN/A
#8
$28.9M20223%N/AN/A
#9
$39.9M2796%N/AN/A
#10
$184.5M101435%N/AN/A
Add Company

What Is Eligo Bioscience?

Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.

keywords:N/A

N/A

Total Funding

54

Number of Employees

$6.3M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Eligo Bioscience News

2022-04-17 - Biotech Tries Manipulating the Skin Microbiome

... is favored by Parisbased biotech company Eligo Bioscience, ... Eligo's platform targets bacterial genes specifically associated with...

2022-04-17 - Biotech Tries Manipulating the Skin Microbiome

... is favored by Parisbased biotech company Eligo Bioscience, ... Eligo's platform targets bacterial genes specifically associated with...

2022-04-13 - Acne Treatment Market Size [2022-2028] worth USD 12.97 Billion | exhibiting a CAGR of 4.8%

January 2021: GlaxoSmithKline plc announced that it entered into an agreement with Eligo BioScience with an aim to advance Eligobiotics for...

2022-04-13 - Acne Treatment Market Size [2022-2028] worth USD 12.97 Billion | exhibiting a CAGR of 4.8%

January 2021: GlaxoSmithKline plc announced that it entered into an agreement with Eligo BioScience with an aim to advance Eligobiotics for...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7M5459%N/A
#2
$7M546%N/A
#3
$7M54N/AN/A
#4
$6.8M5446%N/A
#5
$13.6M5435%N/A